Icon

Onureg - (200 mg and 300 mg ; Tablets)

Azacitidine Celgene
200 mg and 300 mg ; Tablets
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
Yes
** *** **, ****, ******* **** ****** **** ****** '*** ******** ** **** **, ****. ******* **** ****** ******** *******. ********* ** *** ******, *** *********** ******* ** *** **** *** ********* **** *** ****** ******* *********** ****** ****
Onureg Patent 1 Patent 2
****** (*****) ********* ** ****** ** ****** ********* ** ****** ** ******
*** **** ********* ** ****** ** *** ********* ** ****** ** ***
**** ********* ** ****** ** **** ********* ** ****** ** ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** (*****) *** \ ********* *** **, **** ********* ** ****** ** ****** **** ******* *** **, **** (***) *** *** ****
*** **** ** \ ** *** **, **** ********* ** ****** ** ****** **** ******* *** **, **** (***) *** *** ****
**** ** \ ** *** **, **** ********* ** ****** ** **** **** ******* *** **, **** (***) *** *** ****
  1. *** **, **** : * **** ** *** ***** *** ***** ** * *** *******.
  2. *** **, **** : ****** ******** ******* ********* *** **** ** ******.
  3. *** **, **** : ******* **** ****** **** ****** '*** ******** ** **** **, ****.
  4. *** **, **** : ******* ***** ******* **** ******* ****** **** ************ ** ***** ****** ****** '***.
  5. *** **, **** : *** **** ******** ******* ********* *** **** ** ******.
  6. *** **, **** : ******* **** *** **** **** ******* '*** *** '***.
  7. *** **, **** : **** ******** ******* ********* *** **** ** ******.
  8. *** **, **** : ******* **** **** **** ******* '*** *** '***.
  9. *** **, **** : ***** ******** ******* ********* *** **** ** ******.
  10. *** **, **** : ******* **** ***** **** ******* '*** *** '***.
  11. *** **, **** : ******** *** ****** ********* **********. ** ******* ** ** ********* ** ***** ** ******.
  12. *** **, **** : ******** *** *** ********* **********. ** ******* ** ** ********* ** ***** ** ***.
  13. *** **, **** : ******** *** **** ********* **********. ** ******* ** ** ********* ** ***** ** ****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.